Why Some Children Refuse to Eat: First Clinical Trial Identifies Effective Treatments for ARFID

Researchers at the Stanford Medicine have conducted the world's first randomized controlled trial evaluating treatments for avoidant/restrictive food intake disorder (ARFID) in children. The study, published in the Journal of the American Academy of Child & Adolescent Psychiatry, included 98 children aged 6 to 12 years.

Unlike other eating disorders, ARFID is not driven by concerns about body image or weight. Instead, affected children may have little interest in eating or avoid food because of anxiety, fear of choking, or previous negative experiences. The disorder often begins in early childhood and affects an estimated 2% to 6% of children and adolescents, sometimes impairing normal growth and development.

In the study, families were randomly assigned to one of two treatment approaches, each consisting of 14 online therapy sessions delivered over four months.

The first approach was family-based therapy, which places parents at the center of treatment. In this model, parents take the lead in helping their child expand food choices, reduce avoidant eating behaviors, and gradually transfer responsibility for eating back to the child as they mature. Siblings and therapists also participate in the treatment process.

The therapist acts primarily as a consultant, while parents are viewed as the main agents of change. Importantly, the approach emphasizes that children do not choose to have ARFID. Families are encouraged to separate the child's identity from the disorder while consistently addressing restrictive eating behaviors.

The second approach was individual motivational and psychoeducational therapy. In this program, children complete part of the sessions individually using play-based and motivational techniques. They learn about ARFID and gradually build their own motivation to change. Parents play a more limited role, receiving education about the disorder, learning how to reduce conflict around meals, and supporting the changes their child is ready to make.

The results showed that both treatment approaches significantly improved ARFID symptoms. However, family-based therapy produced greater benefits in terms of weight gain. Children in this group experienced statistically significant improvements in body weight, whereas those receiving individual therapy did not show the same effect. Both therapies, however, reduced the overall severity of ARFID symptoms and improved eating behaviors. Family-based therapy was particularly effective in children with more severe forms of the disorder.

ARFID was officially recognized as a distinct diagnosis only in 2013 and is often mistakenly dismissed as simple "picky eating." In reality, the condition can lead to vitamin deficiencies, impaired growth, and serious medical complications, including vitamin C deficiency and scurvy. In some cases, the disorder develops after traumatic experiences such as choking episodes or severe allergic reactions, which can create a persistent fear of eating.

Beyond its physical health effects, ARFID can significantly disrupt daily life. Children may avoid school lunches, family trips, summer camps, and social events involving food, limiting their social participation and quality of life.

According to the researchers, the study's greatest significance is that it provides the first high-quality evidence supporting effective treatments for ARFID in young children. Until now, there had been very few randomized controlled trials investigating how best to treat the disorder.

The authors conclude that while both treatment approaches are effective, family-based therapy may produce faster clinical improvements—particularly in promoting healthy weight gain—whereas individual therapy remains valuable for reducing symptoms and helping children develop a healthier relationship with food.

Follow NEWS.am Medicine on Facebook and Twitter